There appears to be no legal basis for selling BPC-157 as a drug, food, or a dietary supplement, and the Food and Drug Administration (FDA) confirmed there is also no legal basis for compounding pharmacies to use BPC-157 in compounded medications
BPC-157 has been hypothesized to interact with cytokine networks, potentially down-modulating excessive inflammatory responses
Regulatory Status None of GLOW Blend's three components GHK-Cu, BPC-157, or TB-500 is approved by the FDA as a drug for any indication
AHK-Cu Studies and Research Data Research on Angiogenesis and Vascular Growth Scientific investigations indicate that AHK-Cu may play a role in modulating angiogenic processes
By purchasing from our website, customers confirm that they are qualified researchers, laboratories, or research institutions and fully understand the research-use-only designation associated with these products
Other contraindications include uncontrolled thyroid disease, active pituitary disorders, and pregnancy